Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

By BiotechDaily International staff writers
Posted on 18 Aug 2014
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).
For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer.

Ovarian cancer causes more deaths than any other gynecologic cancer. It is the seventh most commonly diagnosed cancer in women worldwide, with an estimated 230,000 cases diagnosed around the world every year and there are approximately 150,000 deaths from the disease. In the European Union, there are an estimated 44,000 cases of ovarian cancer every year, and nearly 30,000 women will die from the disease.

The newly approved drug is bevacizumab, an antibody derived from Chinese hamster ovary cells combined with a mouse protein. It sold in the United States under the brand name Avastin and is manufactured by Genentech (San Francisco, CA, USA), a subsidiary of Roche (Basel, Switzerland).

Avastin works by blocking the action of vascular endothelial growth factor (VEGF). VEGF stimulates the growth of new blood vessels in the process known as angiogenesis. Avastin antibodies bind tightly to VEGF and inactivate it. As a result, new blood vessels are not formed, and cancer tumor growth is inhibited by lack of an adequate supply of blood. Treated tumors cannot get larger and may even shrink. Thus, Avastin does not work directly on the tumor, but prevents its growth by reducing its supply of blood.

The EC has now approved the use of Avastin in combination with the chemotherapeutic drugs paclitaxel, topotecan, or pegylated liposomal doxorubicin as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. Approval was based on results of the phase III AURELIA study, which involved women with recurrent, platinum-resistant ovarian cancer who received either chemotherapy or Avastin in combination with chemotherapy. Results showed that the addition of Avastin to chemotherapy gave a clinically meaningful benefit, nearly doubling the median progression free survival (PFS) from 3.4 months to 6.7 months.

“European approval of Avastin for recurrent, platinum-resistant ovarian cancer is good news because Avastin can help women live longer without their cancer progressing, which is an important treatment goal in advanced disease,” said Dr. Sandra Horning, chief medical officer and head of global product development at Roche. “Avastin is the first biologic medicine approved by the EU for women with this difficult to treat disease.”

Related Links:

Genentech
Roche



Channels

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.